Organisation paid for research Program year 2025 Source: CMS Open Payments

Klein and Associates MD Pa

Neither a doctor nor a teaching hospital

Research payments

$3,743,958

927 payments

Through program year 2025, Klein and Associates MD Pa is reported as receiving $3,743,958 in research payments, across 927 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $388,328 205
2024 Research $220,604 240
2023 Research $93,657 40
2022 Research $259,996 73
2021 Research $1,033,260 140
2020 Research $902,169 119
2019 Research $845,945 110

Breakdown

Who paid Research payments · program years 2019–2025
  1. Gilead Sciences, Inc. $1,120,921 108 payments
  2. AbbVie, Inc. $722,961 272 payments
  3. Ucb SA $714,807 90 payments
  4. Eli Lilly and Company $557,843 49 payments
  5. Amgen Inc. $281,081 7 payments
  6. Janssen Research & Development, LLC $245,104 385 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $61,574 13 payments
  8. UCB, Inc. $34,012 1 payment
  9. Pfizer Inc. $5,655 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $180,398 13 payments
  2. Psa-013/20200058 (Keg) (Foremost) $180,260 2 payments
  3. A Randomized, Controlled Pragmatic Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $170,018 9 payments
  4. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Psa) $164,508 8 payments
  5. Cnto1959psa3004 $137,666 220 payments
  6. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Pso $125,884 2 payments
  7. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis $124,173 12 payments
  8. M16-011 $122,153 33 payments
  9. M15-572 $119,628 31 payments
  10. A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) $107,438 165 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record